What is the recommended management for bullous cellulitis?

Management of Bullous Cellulitis

Treat bullous cellulitis with the same antibiotic regimen as typical cellulitis—a β-lactam active against streptococci—because the presence of bullae does not change the underlying microbiology or require broader empiric coverage in immunocompetent patients. 1

Initial Antibiotic Selection

Standard Empiric Therapy

• Use β-lactam monotherapy (penicillin, amoxicillin, cephalexin, dicloxacillin, or amoxicillin-clavulanate) as first-line treatment, since streptococci remain the primary pathogen even when bullae are present 1
• Oral therapy is appropriate for most patients who lack systemic signs of severe infection 2
• MRSA coverage is NOT routinely indicated for bullous cellulitis; β-lactams cure approximately 96% of typical cellulitis cases 1, 2

When to Add MRSA Coverage

Add anti-MRSA therapy (vancomycin, daptomycin, linezolid, or oral options like doxycycline, clindamycin, or trimethoprim-sulfamethoxazole) only when specific risk factors are present: 1

• Penetrating trauma, especially from intravenous drug use
• Purulent drainage from the lesion
• Concurrent MRSA infection at another site

Special Populations Requiring Broader Coverage

Immunocompromised patients (transplant recipients, neutropenic patients, severe cell-mediated immunodeficiency) warrant consideration of atypical gram-negative organisms: 3, 4

• Obtain blood cultures and consider tissue cultures before starting antibiotics 1, 2
• Broaden coverage empirically to include gram-negative pathogens (e.g., fluoroquinolones or third-generation cephalosporins) while awaiting culture results 3, 4
• E. coli and Pseudomonas species have been documented as rare causes of bullous cellulitis in immunosuppressed patients 3, 4

Admission Criteria vs. Outpatient Management

Admit to Hospital When:

• Hypotension or hemodynamic instability is present 2
• Patient is severely immunosuppressed (neutropenia, malignancy, severe cell-mediated deficiency) 2
• High fever, delirium, or other severe systemic features are evident 1

Manage as Outpatient When:

• Vital signs are normal, patient is afebrile, and mental status is intact 2
• No immunosuppression or severe comorbidities exist 2
• Patient can adhere to oral antibiotics and follow-up appointments 2

Common pitfall: Do not admit patients solely for intravenous antibiotics when they lack high-risk features; oral agents are equally effective and reduce unnecessary hospitalization 2

Adjunctive Therapies

Corticosteroids

• Consider systemic corticosteroids (prednisone 40 mg daily for 7 days) in nondiabetic adults with bullous cellulitis, particularly when hemorrhagic or extensive bullae are present and response to antibiotics alone is inadequate 1, 5
• Hemorrhagic bullous cellulitis may mimic necrotizing fasciitis and often requires adjunctive corticosteroids for complete resolution 5
• The efficacy of corticosteroids is the hallmark distinguishing hemorrhagic/bullous cellulitis from necrotizing fasciitis 5

Supportive Measures

• Elevate the affected limb to promote drainage of edema and inflammatory mediators 1, 2
• Address predisposing conditions such as tinea pedis, onychomycosis, venous insufficiency, or skin barrier disruption 1, 6, 7

Treatment Duration and Monitoring

• A 5-day antibiotic course is as effective as 10 days when clinical improvement is evident by day 5 1, 2
• Expect clinical response within 24–48 hours; failure to improve warrants reassessment for complications (abscess, necrotizing fasciitis) or alternative diagnoses 2
• Note: Bullous cellulitis may have a more protracted course than nonbullous forms, with average hospital stays nearly twice as long (20.6 vs. 10.6 days in one series) 8

Common pitfall: Do not mistake initial worsening of inflammation after starting antibiotics for treatment failure; sudden bacterial lysis can release enzymes that temporarily increase local inflammation 1

Diagnostic Testing

• Blood cultures are NOT routinely needed for typical bullous cellulitis 1, 2
• Obtain blood cultures and consider tissue aspiration or biopsy only when: 1, 2
  • Malignancy is present
  • Severe systemic features exist (high fever, hypotension)
  • Unusual exposures occurred (animal bites, immersion injuries)
  • Patient is neutropenic or severely immunocompromised

Recurrence Prevention

• Address local risk factors: treat tinea pedis and onychomycosis, manage lymphedema and venous insufficiency, optimize skin barrier integrity 1, 6, 7
• Consider antimicrobial prophylaxis (twice-daily oral penicillin or erythromycin) for patients with recurrent episodes despite addressing predisposing factors 1